Cargando…

A flexural exanthem following postexposure prophylaxis

We report a case of symmetrical drug‐related intertriginous and flexural exanthema following antiretroviral postexposure prophylactic medications, tenofovir and emtricitabine, commencement of which preceded the onset of the rash. Tenofovir and emtricitabine are both nucleoside reverse transcriptase...

Descripción completa

Detalles Bibliográficos
Autores principales: Roche, Darren, Murray, Gregg, Hackett, Catriona, Tobin, Anne‐Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313790/
https://www.ncbi.nlm.nih.gov/pubmed/35297086
http://dx.doi.org/10.1111/ced.15131
_version_ 1784754160044867584
author Roche, Darren
Murray, Gregg
Hackett, Catriona
Tobin, Anne‐Marie
author_facet Roche, Darren
Murray, Gregg
Hackett, Catriona
Tobin, Anne‐Marie
author_sort Roche, Darren
collection PubMed
description We report a case of symmetrical drug‐related intertriginous and flexural exanthema following antiretroviral postexposure prophylactic medications, tenofovir and emtricitabine, commencement of which preceded the onset of the rash. Tenofovir and emtricitabine are both nucleoside reverse transcriptase inhibitor medications, commonly used to prevent development of AIDS. [Image: see text]
format Online
Article
Text
id pubmed-9313790
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93137902022-07-30 A flexural exanthem following postexposure prophylaxis Roche, Darren Murray, Gregg Hackett, Catriona Tobin, Anne‐Marie Clin Exp Dermatol Continuing Professional Development We report a case of symmetrical drug‐related intertriginous and flexural exanthema following antiretroviral postexposure prophylactic medications, tenofovir and emtricitabine, commencement of which preceded the onset of the rash. Tenofovir and emtricitabine are both nucleoside reverse transcriptase inhibitor medications, commonly used to prevent development of AIDS. [Image: see text] John Wiley and Sons Inc. 2022-03-17 2022-06 /pmc/articles/PMC9313790/ /pubmed/35297086 http://dx.doi.org/10.1111/ced.15131 Text en © 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Continuing Professional Development
Roche, Darren
Murray, Gregg
Hackett, Catriona
Tobin, Anne‐Marie
A flexural exanthem following postexposure prophylaxis
title A flexural exanthem following postexposure prophylaxis
title_full A flexural exanthem following postexposure prophylaxis
title_fullStr A flexural exanthem following postexposure prophylaxis
title_full_unstemmed A flexural exanthem following postexposure prophylaxis
title_short A flexural exanthem following postexposure prophylaxis
title_sort flexural exanthem following postexposure prophylaxis
topic Continuing Professional Development
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313790/
https://www.ncbi.nlm.nih.gov/pubmed/35297086
http://dx.doi.org/10.1111/ced.15131
work_keys_str_mv AT rochedarren aflexuralexanthemfollowingpostexposureprophylaxis
AT murraygregg aflexuralexanthemfollowingpostexposureprophylaxis
AT hackettcatriona aflexuralexanthemfollowingpostexposureprophylaxis
AT tobinannemarie aflexuralexanthemfollowingpostexposureprophylaxis
AT rochedarren flexuralexanthemfollowingpostexposureprophylaxis
AT murraygregg flexuralexanthemfollowingpostexposureprophylaxis
AT hackettcatriona flexuralexanthemfollowingpostexposureprophylaxis
AT tobinannemarie flexuralexanthemfollowingpostexposureprophylaxis